

**In the Claims**

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-144 (Cancelled)

145. (Currently Amended) A method of inducing tumor cell death, comprising administering to a subject, a therapeutically effective amount of an anti-HLA-DR antibody effective to induce tumor cell death in HLA-DR-expressing tumor cells wherein the therapeutic outcome of the subject is improved following said administration. ~~The method of treating cancer according to claim 144~~ wherein said cancer is selected from the group consisting of multiple myeloma, lymphoma's including Hodgkin's lymphomas, lymphocytic lymphomas and leukemias.

146. (Currently Amended) The method of claim ~~144~~ 145 wherein the anti-HLA-DR antibody is administered intravenously.

147. (Currently Amended) The method of claim ~~144~~ 145 wherein the anti-HLA-DR antibody is administered parenterally.

148. (New) A method for decreasing mitochondrial membrane potential in a mammalian cell, comprising

administering an MHC class II HLA-DR ligand to the mammalian cell to selectively engage MHC class II HLA-DR on the surface of the cell in an amount effective to decrease mitochondrial membrane potential in the mammalian cell, wherein the mammalian cell is not an antigen presenting cell, further comprising the step of contacting the mammalian cell with an amount of an MHC class II HLA-DR inducing agent effective to induce the expression of MHC class II HLA-DR on the surface of the mammalian cell, wherein the MHC class II HLA-DR ligand is an anti-MHC class II HLA-DR antibody.

149. (New) The method of claim 145 wherein the subject is human.

150. (New) The method of claim 148, wherein the mammalian cell is a human tumor cell.